About Arg1-d

This author has not yet filled in any details.
So far Arg1-d has created 14 blog entries.

Listening Session Report

By |2022-03-23T09:42:13-07:00October 11th, 2021|

FDA Family-Led Listening Session Report On June 10, 2021, a group of patients and families affected by Arginase 1 Deficiency (ARG1-D) participated in a one-hour virtual listening session with officials from the Food and Drug Administration (FDA). The session enabled those with ARG1-D and their caregivers to  share their experiences, perspectives, needs, goals with officials [...]

Meet Willow

By |2021-10-11T14:25:55-07:00October 11th, 2021|

Meet Willow Since the moment her mom Tanja realized she was pregnant, her daughter Willow has been full of surprises. Today, Willow is a nurturing, kind, sweet 10-year-old, who loves her new dog Teddy. She is also thoughtful, strong-willed, and stubborn – qualities she needs as she lives with Arginase 1 Deficiency (ARG1-D). Willow [...]

Aeglea BioTherapeutics & Immedica Commercialization Agreement

By |2021-08-25T16:13:41-07:00August 25th, 2021|

Aeglea BioTherapeutics and Immedica Announce Commercialization Agreement for Pegzilarginase for the Treatment of Arginase 1 Deficiency in Europe and Middle East Published: Mar 22, 2021 Original Story HERE AUSTIN, Texas and STOCKHOLM, March 22, 2021 /PRNewswire/ -- Aeglea Biotherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative [...]

Aeglea BioTherapeutics Launches THINK ARGININE™

By |2021-08-25T16:03:27-07:00August 25th, 2021|

Aeglea BioTherapeutics Launches THINK ARGININE™, a Disease Education Initiative to Improve Awareness and Diagnosis of Arginase 1 Deficiency 05/06/2021 Original Story HERE Includes Sponsored Diagnostic Testing and Services for Patients with Suspected Arginase 1 Deficiency AUSTIN, Texas, May 6, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human [...]

Go to Top